Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 2 ... the rabbits were divided into 3 treatment groups: diclofenac sodium ophthalmic solution, bromfenac sodium ophthalmic solution, and betamethasone ophthalmic solution. In each group, the ...
2009 FEB 2 ... be most likely to benefit from treatment with ecabet sodium.
Keywords: Bromfenac Sodium, Clinical Trial Research, Drugs, Dry Eye Syndrome, Eye Disease, FDA, Pharmaceuticals, ...
2009 AUG 17 ... study in subjects with dry eye disease using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom. Combined with our previously announced positive Phase ... in Xibrom. Combined with our previously announced positive Phase 2b results from ecabet sodium, we have established two very compelling candidates in our dry eye franchise. Data from ...
2009 MAY 19 ... 2 proof of concept results in dry eye for a new proprietary, lower dose formulation of bromfenac sodium, the active ingredient in our product, Xibrom.
"We are working ...
2009 JUL 20 ... According to recent research from Tokyo, Japan, "Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal ...
2009 FEB 16 ... aim of this study was to evaluate the ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in subjects undergoing routine cataract surgery with ...
2008 DEC 15 ... from the Company's recently completed Phase III clinical program of Xibrom(TM) (0.09% bromfenac sodium ophthalmic solution) QD (once-daily). The program enrolled 282 patients who underwent ...
2008 APR 21 ... regarding promotional, educational and other activities relating to Xibrom(TM) (bromfenac sodium ophthalmic solution) 0.09%.
It is ISTA's policy to fully comply with all ...
2008 APR 14 ... Inc. (NASDAQ:ISTA), reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ...
2008 OCT 6 ... of any state.
Keywords: ISTA Pharmaceuticals, Clinical Trial Research, Bromfenac Sodium, Xibrom, Pharmaceuticals, Drugs, Therapy, Treatment.
This article was ...
2008 MAY 14 ... Inc., Timolol Maleate, Istalol, Pharmaceuticals, Drugs, Therapy, Treatment, Bromfenac Sodium, Xibrom
This article was prepared by Biotech Week editors from staff and ...
2008 NOV 11 ... Inc., Timolol Maleate, Istalol, Pharmaceuticals, Drugs, Therapy, Treatment, Bromfenac Sodium, Xibrom
This article was prepared by Drug Law Weekly editors from staff ...
